Sustained Long-Term Benefit of Gene Therapy for SMA Sustained Long-Term Benefit of Gene Therapy for SMA

A single infusion of onasemnogene abeparvovec (Zolgensma) provides sustained benefits for up to 6 years in children with SMA, with no new safety signals.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news